Dr. Pablo Cabello Albendea, from the Hospital Ramón y Cajal, emphasizes the importance of reducing the levels of the APOE4 protein in carriers to treat Alzheimer’s disease. A recent study by the “National Institute of Aging” suggests that reducing APOE4 can be therapeutic and that it is crucial to identify and quantify this protein to personalize treatments. Additionally, new gene therapies and strategies combined with anti-amyloid treatments are being explored. Research needs to address when and how to apply these therapies effectively, considering ethnic differences in APOE4 expression.
Published in:
